AMG National Trust Bank cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 71,409 shares of the company's stock after selling 1,925 shares during the quarter. AMG National Trust Bank's holdings in Johnson & Johnson were worth $11,842,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC increased its position in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Northwest & Ethical Investments L.P. lifted its holdings in shares of Johnson & Johnson by 40.7% in the fourth quarter. Northwest & Ethical Investments L.P. now owns 65,024 shares of the company's stock worth $9,404,000 after buying an additional 18,794 shares in the last quarter. Douglass Winthrop Advisors LLC lifted its stake in shares of Johnson & Johnson by 2.2% during the 4th quarter. Douglass Winthrop Advisors LLC now owns 109,409 shares of the company's stock worth $15,823,000 after acquiring an additional 2,357 shares during the last quarter. Finally, Loudon Investment Management LLC grew its holdings in Johnson & Johnson by 1.7% during the 4th quarter. Loudon Investment Management LLC now owns 6,051 shares of the company's stock worth $875,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Trading Up 0.5%
Shares of NYSE:JNJ traded up $0.74 during midday trading on Monday, reaching $164.44. 3,456,993 shares of the company's stock were exchanged, compared to its average volume of 8,123,013. The firm's 50 day simple moving average is $154.29 and its two-hundred day simple moving average is $155.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock has a market cap of $395.66 billion, a price-to-earnings ratio of 17.59, a P/E/G ratio of 2.08 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.82 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.16%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.
Analyst Ratings Changes
Several analysts recently commented on JNJ shares. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Morgan Stanley lifted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday. Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday. Bank of America increased their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday. Finally, Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $172.87.
Read Our Latest Research Report on JNJ
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
